What is the likelihood of ovarian cancer in a postmenopausal woman with stable septated ovarian cysts and a CA125 (Cancer Antigen 125) level of 20-25?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Risk Assessment for Ovarian Cancer in a 60-Year-Old Postmenopausal Woman with Septated Ovarian Cysts

The risk of malignancy is very low (<1%) in this 60-year-old postmenopausal woman with small (≤2 cm) septated ovarian cysts and CA125 values within normal range (20-25 U/mL).

Clinical Features Suggesting Low Risk

  • Small cyst size (2 cm and 1.7 cm x 1.3 cm) is associated with a significantly lower risk of malignancy compared to larger cysts in postmenopausal women 1
  • Stability of the initial cyst for 1 year without growth is a reassuring feature that suggests benign etiology 2
  • Normal CA125 values (20-25 U/mL) are well below the standard threshold of 35 U/mL, which has a specificity of 98.5% for women over 50 years 2
  • CT scan with contrast showing only "follicular changes" without evidence of solid components, papillary projections, or other concerning features 2

Risk Stratification Based on Imaging Features

  • According to the O-RADS US risk stratification system, septated cysts without solid components or papillary projections are classified as low risk 2
  • The presence of a single thin septation (<3 mm) is considered benign with a malignancy risk <0.4% 2
  • Multiple septations without papillary projections or solid components are unlikely to be malignant 2
  • The IOTA Simple Rules classify features such as unilocular cysts, absence of solid components >7mm, and absence of blood flow as benign (B) features 2

Significance of CA125 Levels

  • All patients with CA125 levels <35 U/mL have been found to have benign histopathology regardless of tumor size or ultrasonic features in postmenopausal women 3
  • The specificity of CA125 for detecting ovarian cancer is nearly 100% when using thresholds of 30-35 U/mL 2
  • False-positive CA125 elevations can occur with benign conditions such as endometriosis, adenomyosis, pelvic inflammatory disease, and benign cysts 2, 4
  • This patient's CA125 levels (20-25 U/mL) are well within normal range, further supporting a benign etiology 3

Management Considerations

  • For small (<5 cm) septated cysts with normal CA125 levels in postmenopausal women, conservative management with follow-up imaging is appropriate 1
  • Color or power Doppler should be included in ultrasound examinations to differentiate true solid components from debris and to assess vascularity patterns 2
  • The appearance of a new cyst warrants continued surveillance, but does not significantly increase cancer risk when other features remain reassuring 1

Important Caveats and Pitfalls

  • Even with reassuring features, continued surveillance is recommended as some borderline or low-grade malignant lesions may have normal CA125 levels 2, 5
  • Larger cysts (>5 cm) have a higher risk of harboring undetected malignancy, as papillary formations or solid parts may be missed by transvaginal ultrasonography 6
  • Progressive elevation of CA125 over time, even within normal range, should prompt further evaluation as it may indicate malignancy 2

Conclusion

Based on the current evidence, this patient's presentation with small, stable septated ovarian cysts and normal CA125 values indicates a very low risk (<1%) of malignancy. Continued surveillance with periodic ultrasound and CA125 monitoring is appropriate given the appearance of a new cyst, but immediate intervention is not indicated based on current findings.

References

Guideline

Risk Assessment of Ovarian Cancer in Postmenopausal Women

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cancers Associated with Elevated CA-125 Levels

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

May increased CA125 in borderline ovarian tumor be indicative of a poor prognosis? A case report.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014

Related Questions

What is the initial lab test for a postmenopausal female with ovarian enlargement or cyst?
What is the recommended management for a 61-year-old postmenopausal woman with a new 1.7 cm x 1.3 cm septated ovarian cyst and a CA125 (Cancer Antigen 125) level of 20, given her history of a stable 2 cm septated clear ovarian cyst and a previous CA125 level of 25?
What are the chances of ovarian cancer in a postmenopausal woman with a septated ovarian cyst and mildly elevated Cancer Antigen 125 (CA125) levels?
What are the chances of ovarian cancer in a postmenopausal woman with septated ovarian cysts and normal CA125 levels undergoing total hysterectomy with salpingo-oophorectomy?
What is the likelihood of ovarian cancer in a postmenopausal woman with a new septated ovarian cyst and a Carbohydrate Antigen 125 (CA125) level of 20, given a history of a stable 2 cm clear septated ovarian cyst with a previous CA125 level of 25?
What are the best macronutrients (macronutrients) for weight loss?
Do older adults with type 2B Von Willebrand's disease (VWD) have a higher risk of clinically significant bleeding due to mucosal fragility and increased levels of von Willebrand factor (VWF)?
Is hydroxyurea initiation still recommended for a 23-year-old paraplegic patient?
What to do for persistent low-level anxiety in a patient with Attention Deficit Hyperactivity Disorder (ADHD) on Adderall (amphetamine and dextroamphetamine) 20mg and Escitalopram?
Does location or dysplasia define the risk for oral cancer in oral leukoplakia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.